#KARDIA2

👀 Innovative treatment alert! 🚨 #KARDIA2 trial reveals #zilebesiran, a single-injection drug, significantly lowers systolic BP by up to 12 mm Hg on top of standard meds in patients with resistant hypertension. Benefits last 6 months, paving the way for fewer daily pills.

#Kardia2 study presented by Akshay Desai #LBCT #ACC2024 S/C zilebesiran 600mg: RNAi targeting liver-expressed angiotensinogen 👥Patients with HTN- either uncontrolled (SBP 155-180) or poorly controlled already on HTN agent/s (SBP 145-180) 🏆significant SBP reductions sustained

Promising data, but we need more long term data and of course endpoint studies #ACC24 #Kardia2 #Zilebesiran #hypertension #study

Breaking: Zilebesiran as an add-on therapy in patients with uncontrolled hypertension lowers blood pressure around 10 to 12 mmHg in patients on indapamide and amlodipine respectively #ACC24 #Kardia2 #Zilebesiran #hypertension #study